Literature DB >> 8479323

Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group.

P J Maddison1, C Stephens, D Briggs, K I Welsh, G Harvey, J Whyte, N McHugh, C M Black.   

Abstract

Systemic sclerosis (SSc) tends to occur in a sporadic fashion and familial occurrence of the disease is unusual. Nevertheless, reports of related connective tissue diseases (CTD), autoantibodies, or both in family members together with associations of certain HLA class II phenotypes with SSc suggest that genetic factors might play a part in susceptibility to the disease. Because of the relative rarity of SSc only a small number of family pedigrees have been studied previously. This report represents the largest study to date, to our knowledge, of family members of patients with scleroderma, and provides the opportunity to investigate the relative importance of genetic and environmental factors operating in the disease. The family pedigrees of 63 patients with systemic sclerosis were examined with respect to clinical, serologic, and immunogenetic features. Multiple cases of SSc were seen only in 1 family, in which the disease affected a father and daughter. Disease expression in these 2 individuals was very similar both clinically and serologically; relatives with other connective tissue diseases were found in 9 families, and nonspecific features of CTD such as Raynaud phenomenon, and arthralgia or arthritis, occurred commonly, especially in female relatives. Antinuclear antibodies (ANA) were also detected more frequently in relatives than in controls. However, antibodies previously demonstrated to have a high degree of specificity for SSc were confined to patients with this disease. Probands had an increase in the frequency of HLA-DR3, DR5, and C4AQO. Patients with diffuse scleroderma had an increased frequency of HLA-DR3, while those with the limited form of the disease had an increased frequency of HLA-DR5.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479323     DOI: 10.1097/00005792-199303000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  7 in total

1.  Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis.

Authors:  Walter Serra; Alfredo Chetta; Daniele Santilli; Flavio Mozzani; Pier Paolo Dall'Aglio; Dario Olivieri; Maria Alberta Cattabiani; Diego Ardissino; Tiziano Gherli
Journal:  Cardiovasc Ultrasound       Date:  2010-07-05       Impact factor: 2.062

Review 2.  The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis.

Authors:  M D Mayes
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

3.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

4.  Familial Sneddon's syndrome.

Authors:  A Lossos; T Ben-Hur; Z Ben-Nariah; C Enk; M Gomori; D Soffer
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

Review 5.  The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994.

Authors:  C M Black
Journal:  J R Coll Physicians Lond       Date:  1995 Mar-Apr

6.  Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases.

Authors:  Omar Suhail Alsaed; Laith Ishaq Alamlih; Omar Al-Radideh; Prem Chandra; Samar Alemadi; Abdul-Wahab Al-Allaf
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

7.  Correlation of plasma and urine Wnt5A with the disease activity and cutaneous lesion severity in patients with systemic lupus erythematosus.

Authors:  Shuhong Chi; Jing Xue; Xiaodong Chen; Xiaoming Liu; Yanhong Ji
Journal:  Immunol Res       Date:  2021-12-03       Impact factor: 2.829

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.